KYNTRA BIO, INC.【KYNB】

時価総額

$2980.4万

PER

バイオ医薬品開発の有力企業。希少疾患向けの治療薬と原薬の共同開発・商業供給を展開。AstraZenecaとの提携で2024年12月31日時点の非条件前払金402.2百万ドルを計上。米国、欧州、中国（北京で約67,000平方フィートの拠点、リースは2026年満了）中心に展開。

株価業績

サマリーテーブルに戻る

	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-	-	-	-86	-77	-189	-290	-294	-284	-48
Depreciation	6	6	6	7	11	12	10	10	10	3
Finance Lease, Right-of-Use Asset, Amortization	-	-	-	-	10	10	5	1	0	0
Net accretion of premium and discount on investments	-	-	-	0	4	-0	-2	-2	5	2
Unrealized loss on equity investments	-	-	-	-	-	-	-0	-	-	-
Investment income in unconsolidated variable interest entity	-	-	-	-	-	-	1	2	3	4
Loss on disposal of property and equipment	-0	-	-0	-0	0	-1	-0	0	-0	-3
Stock-based compensation	28	32	38	52	66	73	71	66	51	25
Acquired in-process research and development expenses	-	-	-	-	-	-	-	-	25	-
Dividend received from unconsolidated variable interest entity	-	-	-	-	-	-	-	-	2	2
Accounts receivable, net	2	-5	-2	55	-35	12	-25	-1	-3	7
Inventories	-	-	-	-	7	9	14	11	2	-22
Prepaid expenses and other current assets	-1	-1	2	0	129	-123	10	-5	28	16
Operating lease right-of-use assets	-	-	-	-	-	-	-4	-11	-12	-66
Other assets	0	0	2	-1	3	-7	4	-0	-0	-1
Accounts payable	2	-0	-1	4	-3	18	1	6	-16	15
Accrued and other liabilities	-	-	-	-	18	31	16	91	-50	-94
Operating lease liabilities, current	-	-	-	-	-	-	1	-1	4	-13
Deferred revenues	-	-	-	-5	-50	45	58	-4	-28	-28
Accrued interest expense related to sale of future revenues	-	-	-	-	-	-	-	-	-	2
Accrued interest for finance lease liabilities	-	-	-	-	0	-0	-0	0	-0	0
Operating lease liabilities, non-current	-	-	-	-	-	-	-4	-9	-13	-66
Other long-term liabilities	4	2	2	2	52	-28	-12	-18	-3	-1
Net cash used in operating activities	-	-	-	-76	-79	82	-82	-146	-315	-138
Purchases of property and equipment	2	1	9	8	6	4	5	4	3	0
Payment made for acquired in-process research and development asset	-	-	-	-	-	-	25	35	-	-
Proceeds from sale of property and equipment	0	-	0	0	0	-	-	0	-	1
Purchases of available-for-sale securities	-	-	-	-	-	-	484	164	252	9
Cash Acquired from Acquisition	-	-	-	-	-	-	-	-	1	-
Proceeds from sales of available-for-sale securities	-	-	-	-	-	-	4	7	7	-
Proceeds from maturities of investments	-	-	-	54	537	457	83	284	401	134
Net cash provided by investing activities	-	-	-	-522	120	452	-427	89	154	126
Proceeds from Issuance of Secured Debt	-	-	-	-	-	-	-	-	74	-
Cash paid for transaction costs for senior secured term loan facilities	-	-	-	-	-	-	-	-	3	-
Repayments of finance lease liabilities	-	-	-	-	12	13	5	0	0	0
Repayments of lease obligations	-	-	-	0	0	0	0	0	0	-
Cash paid for payroll taxes on restricted stock unit releases	-	3	8	16	13	11	7	5	0	0
Proceeds From Sale Of Future Revenues Net Of Issuance Costs	-	-	-	-	-	-	-	50	-	-
Cash paid for transaction costs related to sale of future revenues	-	-	-	-	-	-	-	1	-	-
Proceeds from Issuance Initial Public Offering	-	-	-	-	-	-	-	-	48	-
Proceeds from Issuance of Common Stock	13	10	35	30	21	38	13	4	4	0
Net cash (used in) provided by financing activities	-	-	-	14	-4	13	-1	47	123	-0
Effect of exchange rate change on cash and cash equivalents	-	-	-	-0	-0	5	3	-5	-3	1
Net increase (decrease) in cash and cash equivalents	-	-	-	-584	37	552	-507	-16	-42	-12
Non cash acquisition in Fortis	-	-	-	-	-	-	-	-	-22	-
Interest payments	0	0	0	0	0	0	0	0	0	16
Capital Expenditures Incurred but Not yet Paid	1	0	4	0	0	1	1	0	0	-
Cash and cash equivalents of continuing operations	-	-	-	-	-	-	-	-	-	50